Meta-analysis of the relation between the VDR gene TaqIpolymorphism and genetic susceptibility to prostate cancer in Asian populations

Asian Pacific Journal of Cancer Prevention

Volumn 13, Issue 9, 2012, Pages 4441-4444

  Guo, Ya Jie ^a   Shi, Ze Ming ^a   Liu, Jun Da ^a   Lei, Ning ^a   Chen, Qiu Hong ^a   Tang, Ying ^a  

^a CHENGDU UNIVERSITY OF TECHNOLOGY   (China)

Author keywords

Asian populations; Meta analysis; Prostate cancer; Taq I; Vitamin D receptor

Indexed keywords

EID: 84874016721     PISSN: 15137368     EISSN: 2476762X     Source Type: Journal    
DOI: 10.7314/APJCP.2012.13.9.4441     Document Type: Article

References (31)

1. Bao BY, Yeh SD, Lee YF (2006). 1alpha,25-dihydroxyvitamin D3 inhibits prostate cancer cell invasion via modulation of selective proteases. Carcinogenesis, 27, 32-42.
2. Bai Y, Yu Y, Yu B, et al (2009). Association of vitamin D receptor polymorphisms with the risk of prostate cancer in the Han population of Southern China. BMC Med Genet, 10, 125.
3. Bid HK, Mishra DK, Mittal RD (2005). Vitamin-D receptor (VDR) gene (Fok-I, Taq-I and Apa-I) polymorphisms in healthy individuals from north Indian population. Asian Pac J Cancer Pre, 6, 147-52.
4. Campbell MJ, Elstner E, Holden S, et al (1997). Inhibition of proliferation of prostate cancer cells by a 19-nor-hexafluoride vitamin D3 analogue involves the induction of p21waf1, p27kip1 and Ecadherin. J Mol Endocrinol, 19, 15-27.
5. Cariati F, Negri A, Pivonello C, et al (2012). Vitamin D from genetics to the clinical in prostate cancer. Endocrine Abstracts, 29, P836.
6. Chaimuangraj S, Thammachoti R, Ongphiphadhanakul B, et al(2006). Lack of association of VDR polymorphisms with Thai prostate cancer as compared with benign prostate hyperplasia and controls. Asian Pac J Cancer Prev, 7, 136-9.
7. Corder EH, Guess HA, Hulka BS et al (1993).Vitamin D and prostate cancer: a prediagnostic study with stored sera. Cancer Epidemiol Biomarkers Prev, 2, 467-72.
8. Dersimonian R, Laird N (1986). Meta-analysis in clinical trials. Control Clin Trials, 7, 177-88.
9. Habuchi T, Suzuki T, Sasaki R, et al (2000). Association of vitamin D receptor gene polymorphism with prostate cancer and benign prostatic hyperplasia in a Japanese population. Cancer Res, 60, 305-8.
10. Hamasaki T, Inatomi H, Katoh T, et al (2001).Clinical and pathological significance of vitamin D receptor gene polymorphism for prostate cancer which is associated with a higher mortality in Japanese. Endocr J, 48, 543-9.
11. Hamasaki T, Inatomi H, Katoh T, et al (2002). Significance of vitamin D receptor gene polymorphism for risk and disease severity of prostate cancer and benign prostatic hyperplasia in Japanese. Urol Int, 68, 226-31.
12. Hidalgo AA, Paredes R, Garcia VM, et al (2007). Altered VDR-mediated transcriptional activity in prostate cancer stroma. J Steroid Biochem Mol Biol, 103, 731-6.
13. Huang SP, Chou YH, Wayne Chang WS, et al (2004).Association between vitamin D receptor polymorphisms and prostate cancer risk in a Taiwanese population. Cancer Lett, 207, 69-77.
14. Jemal A, Siegel R, Ward E, et al (2009). Cancer statistics, 2009. CA Cancer J Clin, 59, 225-49.
15. Jose S, George PS, Mathew A (2008). Assessment of confounding and interaction using the mantel-haenszel risk estimation method. Asian Pac J Cancer Prev, 9, 323-5.
16. Krishnan AV, Peehl DM, Feldman D (2003). Inhibition of prostate cancer growth by vitamin D: Regulation of target gene expression. J Cell Biochem, 88, 363-71.
17. Li M, Zhang S, Ma J, et al (2009). A comparative study on incidence trends of prostate cancer in part of cities and counties in China. Chin J Urol, 30, 368-70. (article in China)
18. Liu J, Li H, Gu L, et al (2004a). Association between VDRG 3' polymorphisms and prostate cancer in Chinese population. Chin J Clin Rehab, 8, 3429-32. (article in China)
19. Liu J, Li H, Tong M, et al (2004b). Susceptibility gene polymorphism and risk of prostate cancer in Chinese population. Nat Med J China, 84, 364-8. (article in China)
20. Moon SJ, Fryer AA, Strange RC (2005). Ultraviolet radiation: effects on risks of prostate cancer and other internal cancers. Mutat Res, 571, 207-19.
21. Onsory K, Sobti RC, Al-Badran AI, et al (2008). Hormone receptor-related gene polymorphisms and prostate cancer risk in North Indian population. Mol Cell Biochem, 314,25-35.
22. Schaid DJ(2004).The complex genetic epidemiology of prostate cancer. Hum Mol Genet, 13, R103-21.
23. Schwartz GG (2012). Circulating vitamin D and risk of prostate cancer--letter. Cancer Epidemiol Biomarkers Prev, 21, 246.
24. Schwartz GG, Hulka BS (1990). Is vitamin D deficiency a risk factor for prostate cancer? (Hypothesis). Anticancer Res, 10, 1307-11.
25. Suzuki K, Matsui H, Ohtake N, et al (2003).Vitamin D receptor gene polymorphism in familial prostate cancer in a Japanese population. Int J Urol, 10, 261-6.
26. Vieira AR (2006). Association between the transforming growth factor alpha gene and nonsyndromic oral clefts: a HuGE review. Am J Epidemiol, 163, 790-810.
27. Watanabe M, Fukutome K, Murata M, et al (1999).Significance of vitamin D receptor gene polymorphism for prostate cancer risk in Japanese. Anticancer Res, 19, 4511-4.
28. Williamson PR, Gamble C, Altman DG, et al (2005). Outcome selection bias in meta-analysis. Stat Methods Med Res, 14, 515-24.
29. Ylikomi T, Laaksi I, Lou YR, et al (2002).Antiproliferative action of vitamin D. Vitam Horm, 64, 357-406.
30. Zhang WB, Zhang JH, Pan ZQ, et al (2012). The MTHFR C677T Polymorphism and Prostate Cancer Risk: New Findings from a Meta-analysis of 7306 Cases and 8062 Controls. Asian Pac J Cancer Prev, 13, 2597-604.
31. Zmuda JM, Cauley JA, Ferrell RE (2000).Molecular epidemiology of vitamin D receptor gene variants. Epidemiol Rev, 22, 203-17.